[Pharmacoeconomic evaluation of use of ciprofloxacin and norfloxacin with cost-benefit analysis].
Pharmacoeconomics is application of economical principles in health and pharmaceutical care sector. This is comparative analysis of treatment e.i. therapeutic alternatives (drugs), which takes into consideration both their costs and their health repercussions. Cost-benefit analysis (CBA) has been used where effectiveness of cost was calculated by calculating the sum of costs for urinary infections treatment which include the cost of examinations, the costs of therapy with ciprofloxacin and norfloksacin, other costs associated with treatment and total benefit for both of treatments. CBA of costs are pointing out that it is economically justified to prescribe both drugs, ciprofloxacin and norfloksacin, due the costs-benefit are the quite equal for both.
Skrbo
Armin
A
Farmaceutski fakultet Univerziteta u Sarajevu.
Selava
Aida
A
Zunić
Lejla
L
D000328:Adult; D000890:Anti-Infective Agents / Q000191:economics* / Q000627:therapeutic use; D017522:Bosnia and Herzegovina; D002939:Ciprofloxacin / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D006801:Humans; D009643:Norfloxacin / Q000191:economics* / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000191:economics*
D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D009643:Norfloxacin